Literature DB >> 16271707

Differential interactions of G-proteins and adenylyl cyclase with nucleoside 5'-triphosphates, nucleoside 5'-[gamma-thio]triphosphates and nucleoside 5'-[beta,gamma-imido]triphosphates.

Andreas Gille1, Jianxin Guo, Tung-Chung Mou, Michael B Doughty, Gerald H Lushington, Roland Seifert.   

Abstract

The regulatory G-proteins of adenylyl cyclase (AC), G(i) and G(s), are not only activated by GTP and the stable GTP analogs, guanosine 5'-[gamma-thio]triphosphate (GTPgammaS) and guanosine 5'-[beta,gamma-imido]triphosphate (GppNHp), but also by hypoxanthine, xanthine, uracil and cytidine nucleotides. The latter nucleotides were previously used to analyze distinct active G-protein states. Surprisingly, recent studies have shown that inosine 5'-[gamma-thio]triphosphate and uridine 5'-[gamma-thio]triphosphate can also inhibit AC directly. Therefore, we systematically compared the interactions of nucleoside 5'-triphosphates (NTPs), nucleoside 5'-[gamma-thio]triphosphates (NTPgammaSs) and nucleoside 5'-[beta,gamma-imido]triphosphates (NppNHps) with G(i), G(s) and AC. NTPgammaSs exhibited up to 26,000-fold higher affinity for G-proteins than NTPs and NppNHps. NTPgammaSs were up to 150-fold more potent direct AC inhibitors than NTPs and NppNHps. G-proteins exhibited striking preference for guanine nucleotides compared to other purine and pyrimidine nucleotides, whereas base-selectivity of various ACs, particularly the purified catalytic subunits C1.C2, was rather poor. GTP, GTPgammaS and GppNHp exhibited much higher selectivity for G-proteins relative to AC than all other purine and pyrimidine nucleotides. We have energetically characterized the interactions of purine and pyrimidine nucleotides with AC in silico, constructing pharmacophore models that correlate well with experimental affinities and have elucidated specific amino acid residues with greatest influence on nucleotide binding. Collectively, both G-proteins and ACs bind purine and pyrimidine nucleotides, with G-proteins showing much higher base-selectivity than AC. Thus, direct inhibitory effects of nucleotides on AC should be understood and considered when probing distinct active G-protein states with non-guanine nucleotides.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16271707     DOI: 10.1016/j.bcp.2005.10.006

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Inhibition of the adenylyl cyclase toxin, edema factor, from Bacillus anthracis by a series of 18 mono- and bis-(M)ANT-substituted nucleoside 5'-triphosphates.

Authors:  Hesham Taha; Stefan Dove; Jens Geduhn; Burkhard König; Yuequan Shen; Wei-Jen Tang; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-24       Impact factor: 3.000

2.  A conformational transition in the adenylyl cyclase catalytic site yields different binding modes for ribosyl-modified and unmodified nucleotide inhibitors.

Authors:  Jenna L Wang; Jian-Xin Guo; Qi-Yuan Zhang; Jay J-Q Wu; Roland Seifert; Gerald H Lushington
Journal:  Bioorg Med Chem       Date:  2007-02-11       Impact factor: 3.641

3.  Structural basis for the high-affinity inhibition of mammalian membranous adenylyl cyclase by 2',3'-o-(N-methylanthraniloyl)-inosine 5'-triphosphate.

Authors:  Melanie Hübner; Anshuman Dixit; Tung-Chung Mou; Gerald H Lushington; Cibele Pinto; Andreas Gille; Jens Geduhn; Burkhard König; Stephen R Sprang; Roland Seifert
Journal:  Mol Pharmacol       Date:  2011-04-15       Impact factor: 4.436

Review 4.  Interaction of nucleoside diphosphate kinase B with heterotrimeric G protein betagamma dimers: consequences on G protein activation and stability.

Authors:  Thomas Wieland
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-03       Impact factor: 3.000

5.  Differential inhibition of various adenylyl cyclase isoforms and soluble guanylyl cyclase by 2',3'-O-(2,4,6-trinitrophenyl)-substituted nucleoside 5'-triphosphates.

Authors:  Srividya Suryanarayana; Martin Göttle; Melanie Hübner; Andreas Gille; Tung-Chung Mou; Stephen R Sprang; Mark Richter; Roland Seifert
Journal:  J Pharmacol Exp Ther       Date:  2009-06-03       Impact factor: 4.030

6.  Molecular analysis of the interaction of anthrax adenylyl cyclase toxin, edema factor, with 2'(3')-O-(N-(methyl)anthraniloyl)-substituted purine and pyrimidine nucleotides.

Authors:  Hesham M Taha; Jennifer Schmidt; Martin Göttle; Srividya Suryanarayana; Yuequan Shen; Wei-Jen Tang; Andreas Gille; Jens Geduhn; Burkhard König; Stefan Dove; Roland Seifert
Journal:  Mol Pharmacol       Date:  2008-12-04       Impact factor: 4.436

7.  Structure-activity relationships for the interactions of 2'- and 3'-(O)-(N-methyl)anthraniloyl-substituted purine and pyrimidine nucleotides with mammalian adenylyl cyclases.

Authors:  Cibele Pinto; Gerald H Lushington; Mark Richter; Andreas Gille; Jens Geduhn; Burkhard König; Tung-Chung Mou; Stephen R Sprang; Roland Seifert
Journal:  Biochem Pharmacol       Date:  2011-05-18       Impact factor: 5.858

Review 8.  Inhibitors of membranous adenylyl cyclases.

Authors:  Roland Seifert; Gerald H Lushington; Tung-Chung Mou; Andreas Gille; Stephen R Sprang
Journal:  Trends Pharmacol Sci       Date:  2011-11-17       Impact factor: 14.819

9.  Impairment of adenylyl cyclase 2 function and expression in hypoxanthine phosphoribosyltransferase-deficient rat B103 neuroblastoma cells as model for Lesch-Nyhan disease: BODIPY-forskolin as pharmacological tool.

Authors:  Liz Kinast; Juliane von der Ohe; Heike Burhenne; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-03       Impact factor: 3.000

10.  Crystal structure of the guanylyl cyclase Cya2.

Authors:  Annika Rauch; Martina Leipelt; Michael Russwurm; Clemens Steegborn
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.